Neogen (NASDAQ: NEOG) reported fiscal Q1 2027 revenue of $222.8 million, up 6.5% from $209.2 million, while diluted EPS was a loss of $0.05 versus earnings of $0.17 a year earlier. Adjusted EBITDA increased 17.2% to $41.6 million, and its margin expanded to 18.7%, reflecting higher revenue and operating leverage. The GAAP earnings comparison was affected by a $76.4 million divestiture gain recorded in the prior-year quarter.

Core Earnings Data

For the three months ended August 31, 2026, core revenue increased 8.1% after excluding foreign exchange, divestitures, and discontinued product lines. Neogen said the core growth rate included an approximately 3% benefit related to distributor inventory adjustments in the prior-year period and the timing of certain customer orders this quarter.

Reported gross margin increased by 200 basis points, while the operating loss narrowed by $14.3 million. On an adjusted basis, net income rose to $17.5 million and adjusted EPS doubled to $0.08.

Prior-year free cash flow is calculated using Neogen’s definition of operating cash flow less purchases of property, equipment, and intangible assets.

Business and Segment Performance

Food Safety remained Neogen’s largest growth contributor. Segment revenue increased 7.4% to $163.2 million, with core growth of 8.1%. Indicator Testing and Culture Media revenue rose to $85.6 million from $76.8 million, supported by Petrifilm, while Bacterial and General Sanitation revenue increased to $44.6 million from $41.6 million, including growth in pathogen-detection products.

Animal Safety revenue increased 4.2% to $59.6 million, while core growth reached 8.0%. Veterinary Instruments and Consumables rose to $14.1 million from $11.9 million, and Genomics Services increased to $17.3 million from $16.5 million. Total Animal Safety biosecurity revenue edged down to $18.9 million from $19.2 million, although management cited strength in insect-control products within the category.

Domestic revenue increased to $110.1 million from $102.1 million, while international revenue rose to $112.7 million from $107.1 million. Neogen reported growth in every global region, including double-digit growth in Asia Pacific.

Lower Integration Costs Drove Most of the Reported Margin Expansion

GAAP gross margin increased to 47.4% from 45.4%, primarily because costs related to integrating the former 3M Food Safety business declined. Adjusted gross margin, which removes specified integration and other items, increased more modestly to 49.8% from 49.5%. The difference indicates that lower integration costs accounted for much of the reported gross-margin improvement.

Operating expenses declined to $107.3 million from $111.1 million despite revenue growth. That combination narrowed the GAAP operating loss and lifted adjusted operating margin to 16.4% from 14.1%. Management attributed the adjusted EBITDA margin expansion mainly to higher revenue creating operating leverage against expenses.

The year-over-year drop in GAAP net income does not provide a direct comparison of underlying operations. The prior-year result included a $76.4 million non-cash gain from the sale of the Cleaners & Disinfectants business. Excluding specified items, adjusted net income improved because of higher EBITDA and lower interest and income tax expense.

Cash Flow and Balance Sheet

Free cash flow improved as operating cash flow increased and capital expenditures declined to $8.2 million from $24.0 million. Neogen used $20.0 million to repay debt during the quarter, and non-current debt declined to $774.2 million from $793.7 million at the end of fiscal 2026.

Cash and equivalents decreased by $13.5 million during the quarter to $172.0 million. The decline reflected the debt repayment and capital spending, partly offset by operating cash generation. Inventory increased modestly to $146.1 million from $144.3 million, while net interest expense declined to $13.8 million from $15.5 million.

Fiscal 2027 Guidance

Neogen raised both ends of its fiscal 2027 revenue range by $5 million and both ends of its adjusted EBITDA range by $1 million. The revision lifts the expected midpoints to $887.5 million for revenue and $182 million for adjusted EBITDA.

Adjusted EBITDA is a non-GAAP measure. Neogen did not provide a forward-looking reconciliation to GAAP net income because several excluded items, including integration, restructuring, transformation, impairment, and stock-compensation expenses, cannot be forecast without unreasonable effort.

Management Priorities and Operational Milestones

Management said its focus has shifted from strengthening operating fundamentals to scaling them through greater commercial discipline, a harmonized sales model, renewed innovation, inventory optimization, and improved customer service. The company is making targeted investments while seeking more consistent long-term growth and margin expansion.

Neogen remains on schedule to manufacture saleable Petrifilm products and begin a multi-quarter transition to its Lansing facility in November 2026. The first SKU was fully validated in August. Petrifilm duplicate manufacturing costs increased to $4.7 million from $2.3 million and were excluded from adjusted EBITDA, making transition costs an important item to monitor as production moves forward.

The proposed sale of Neogen’s global Genomics business to Zoetis remains subject to closing conditions and regulatory reviews, which the company currently expects to conclude by the end of December 2026.

Recent Insider Transactions

The latest supplied transaction data was dominated by direct stock awards issued on August 14, 2026. CEO Mikheal Nassif also reported a small indirect purchase on August 4; these entries do not by themselves indicate management’s view of the company’s valuation or outlook.

The supplied six-month summary reported zero purchases despite purchase entries appearing in the detailed transaction list, so the two data sets use different classifications or contain a reporting inconsistency.

Risks for Investors to Watch

• Revenue timing: Core growth included an approximately 3% benefit from prior-year distributor inventory adjustments and the timing of customer orders. This benefit may make the quarter’s growth rate difficult to compare with subsequent periods.
• Petrifilm transition execution: The production transfer is expected to take multiple quarters, and duplicate manufacturing costs have already increased. Delays or additional transition costs could affect margins and customer service.
• GAAP profitability and debt costs: Neogen remained loss-making on a GAAP basis and carried $774.2 million of non-current debt. Although interest expense declined, it continued to weigh on net income and cash generation.
• Genomics divestiture timing: Completion of the Zoetis transaction remains subject to regulatory review and other closing conditions, creating uncertainty around timing and future business comparability.

Summary

Neogen’s fiscal Q1 2027 results showed higher reported and core revenue, improving operating leverage, and better cash generation. Food Safety led reported segment growth, while lower integration costs supported the improvement in GAAP gross margin. The raised annual guidance points to higher full-year expectations, but investors will need to monitor the temporary revenue-timing benefit, Petrifilm transition costs, leverage, and completion of the Genomics divestiture.

Find out more